No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
JSPR Jasper Therapeutics
- 21.070
- -0.960-4.36%
Trading Apr 25 14:06 ET
317.85MMarket Cap-3409P/E (TTM)
21.570High20.550Low48.02KVolume21.500Open22.030Pre Close1.02MTurnover0.51%Turnover RatioLossP/E (Static)15.09MShares31.01052wk High4.05P/B199.77MFloat Cap4.00052wk Low--Dividend TTM9.48MShs Float188.800Historical High--Div YieldTTM4.63%Amplitude3.862Historical Low21.156Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market
Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) Market Cap Dropped US$88m Last Week; Individual Investors Who Hold 36% Were Hit as Were Institutions
Key Insights The considerable ownership by individual investors in Jasper Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 12 investors
Express News | Jasper Therapeutics Shares Are Trading Higher After Evercore ISI Initiated Coverage on the Stock With an Outperform Rating and $65 Price Target
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Evercore ISI Group Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $65
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $65.
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
PDF Version REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
Comments
$Jasper Therapeutics(JSPR.US$ hmmmm, reverse split tomorrow and then gets halted 10 minutes before close pending news. interesting
ColumnsWith the release of GPT4, the vertical collar or application of related multi-modal large models may be further developed
The application scenarios related to multi-modal large models will gradually become popular with the improvement of significant model capabilities and cost reduction. The US stock market recommends paying attention to the following:
Microsoft$Microsoft(MSFT.US$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
Microsoft$Microsoft(MSFT.US$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
5
Pretty sure, todays 8%+ daily candle (+ AH gains) should be enough to enable 5 day moving average to gain from other 3 daily MA’s. If no significant pre-market action, I HOPE to see it open running
$Jasper Therapeutics(JSPR.US$ look how close the 5, 10, 20 & 30 day moving avergaes are on daily scale. To be honest, I don’t think I’ve seen a Stock like this before that has run 350% in one day consolidate to such tight parameters. Hopefully the price remains a current level or higher at open tomorr...
5
11
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg